Clinical Trials Logo
  1. Home
  2. Hematologic Malignancies
  3. NCT01375842

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Hematologic Malignancies Clinical Trial

Official title:
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Clinical Trial Summary

This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01375842
Study type Interventional
Source Genentech, Inc.
Contact
Status Completed
Phase Phase 1
Start date June 21, 2011
Completion date September 30, 2018
View Details
See also
  Status Clinical Trial Phase
Suspended NCT01562626 - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Phase 1/Phase 2
Completed NCT00435669 - A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) Phase 1
Completed NCT00400023 - A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors Phase 1
Completed NCT00372437 - A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine Phase 1/Phase 2
Completed NCT00410696 - Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Phase 2
Completed NCT00395434 - Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors Phase 1
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Recruiting NCT00553033 - Laparoscopic Liver Resection N/A
Completed NCT00248404 - NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Phase 1/Phase 2
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Terminated NCT03251924 - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05103969 - Cohort of Tumors With POLE/D1 Mutation
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Completed NCT02275910 - Phase 1 Study of E7090 in Subjects With Solid Tumor Phase 1
Terminated NCT02271516 - to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage Phase 1
Completed NCT01448759 - Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel N/A
Terminated NCT01081808 - Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors Phase 1
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00389480 - Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1